Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 8/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.76 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.59 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.59 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189411 | 1.00 | SLCO1B1 (0.76) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL19715666 | 0.90 | SLCO1B1 (0.75) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL19715650 | 0.90 | SLCO1B1 (0.75) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL19715727 | 0.88 | SLCO1B1 (0.80) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL22477575 | 0.88 | SLCO1B1 (0.58) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL22477471 | 0.88 | SLCO1B1 (0.58) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL19715809 | 0.87 | SLCO1B1 (0.98) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL19715725 | 0.87 | SLCO1B1 (0.78) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL23743652 | 0.86 | SLCO1B1 (1.00) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 | |
| SCHEMBL19715717 | 0.86 | SLCO1B1 (1.00) | SLCO1B1ABCB11ABCC3ABCC4SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-20 | — | — | US | disclosed |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-12-07 | — | — | US | disclosed |
| US-RE49352-E1 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-RE49352-E1 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-08-11 | — | — | US | disclosed |
| CN-114601830-A | Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-109963843-B | Carbamoyloxymethyltriazolylcyclohexanes as LPA antagonists | 百时美施贵宝公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3666771-B1 | LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3666771-B1 | LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3472148-B1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | CHENG PETER TAI WAH (US) | 2018-11-22 | — | — | US | disclosed |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360759-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-20220249443-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-20210244711-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-20200138789-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-20230390249-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-10576062-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-20250057815-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-20180333395-A1 | CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
| US-10071078-B2 | Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1507/4885ABCB11 2022/4885ABCC3 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.